DOI: 10.1055/s-00035331

Revista Urología Colombiana / Colombian Urology Journal

References

Sandhu SK, Hussain M, Mateo J. , et al.
PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations.

Ann Oncol 2019;
30 (November): ix188-ix189

Download Bibliographical Data

Search in:
Access: